Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host epithelial barrier
- Molecular classification
- Other (represents a multicellular structural barrier, not a molecular family such as a receptor or transporter)
01
Overview
The host epithelial barrier refers to the thin, continuous lining formed by epithelial cells covering mucosal surfaces such as the gastrointestinal tract. These cells—joined by tight junctions and covered by mucus—serve as the frontline physical and biochemical defense against pathogens, toxins, and other antigens. The barrier balances permeability to nutrients and fluids against exclusion of harmful organisms, supporting immune tolerance to commensals while enabling the immune response to pathogens. Dysfunction or disruption of the epithelial barrier is implicated in a broad spectrum of diseases, from chronic inflammation and infection to cancer and metabolic disorders[1][2][3][4][5].
- Other names
- Epithelial barrierIntestinal epithelial barrierMucosal epithelial barrier
02
Mechanism of action
Enhancement of tight junction integrity (e.g., probiotics modulating tight junction protein phosphorylation); Modulation of mucin production (indirect action by dietary changes, certain drugs, or probiotics); Inhibition of epithelial cell shedding (experimental approaches)
03
Biological functions
Physical barrier to pathogens and toxinsMaintenance of epithelial integrityRegulation of immune response and immune toleranceSelective nutrient and ion transportHost-microbiota interactions and homeostasis
04
Disease associations
Inflammatory bowel disease (IBD)InfectionCancer (notably colorectal cancer via barrier dysfunction)Obesity and metabolic disordersAutoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis)
05
Safety considerations
Targeting barrier function can inadvertently increase infection risk or alter tolerance for commensal microbesOff-target modulation could disturb immune homeostasis or nutrient absorption
06
Interacting drugs
Probiotic bacteria (e.g., Lactobacillus rhamnosus, L. acidophilus)
1 more in the full profile.
07
Biomarkers
Intestinal permeability assays (e.g., lactulose-mannitol test)Levels of tight junction proteins (occludin, claudins, zonula occludens)Mucin content in stool
Beyond the preview
Go deeper on Host epithelial barrier.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Host epithelial barrier.